Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Josh Enomoto

Carl Icahn Gets a Taste of His Own Medicine with the Icahn Enterprises (IEP) Decline

What turned out to be a slow year for billionaire Carl Icahn’s conglomerate Icahn Enterprises (IEP) has become decidedly worse, with IEP stock now staring at a nearly 38% loss since the start of January. Last week, shares of the activist investor’s firm came under the crosshairs of Hindenburg Research. Now, with IEP facing the glare of a federal investigation, circumstances don’t look swell for the entity.

To be sure, retail investors of IEP stock won’t take too kindly to Hindenburg, which natively arouses controversy for its short-selling specialty. Essentially, Hindenburg researches potentially overvalued companies, seeking a downward correction. At the same time, it initiates a short position on the targeted enterprises, profiting from their slide (so long as circumstances align to their intentions).

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.